Brain Cancer Clinical Trials in Cleveland

Showing 201-220 of 226 trials

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

NCT00024570

IL13-PE38QQR is an oncology drug product consisting of IL13 (interleukin-13) and PE38QQR (a bacteria toxin). IL3-PE38QQR is a protein that exhibits cell killing activity against a variety of IL13 receptor-positive tumor cell lines indicating that it may show a therapeutic benefit. In reciprocal competition experiments, the interaction between IL13-PE38QQR and the IL13 receptors was shown to be highly specific for human glioma cells. IL13-PE38QQR will be infused in two courses of 96 hours each, eight weeks apart, directly into the malignant brain tumors of patients to determine the dose of drug these patients can tolerate. After that, the selected dose will be studied to give an estimate of the response rate, response duration, time to response, and survival after infusing that dose of IL13-PE38QQR into the recurrent malignant glioma.

Malignant GliomaGlioblastoma MultiformeAnaplastic Astrocytoma+1 more

INSYS Therapeutics Inc60 participantsStarted Nov 2000

Birmingham, Alabama, United States • Tampa, Florida, United States • Atlanta, Georgia, United States +5 more locations

COMPLETED< 1 mile

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00003096

RATIONALE: Analyzing the number and structure of genes found in a child's cancer cells may help doctors improve methods of diagnosing and treating children with brain tumors. PURPOSE: This clinical trial is studying the number and structure of genes in cancer cells of children with brain tumors.

Brain TumorsCentral Nervous System Tumors

Children's Oncology Group88 participantsStarted Dec 1996

Phoenix, Arizona, United States • Downey, California, United States • Loma Linda, California, United States +58 more locations

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

Brain Cancer Trials in Other Cities

Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme

Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Tolerability Study of Xerecept® in Pediatric Patients

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Other Conditions in Cleveland